Premaitha Health (AIM: NIPT) is an innovative molecular diagnostics company bringing advantages in Next Generation DNA sequencing to non-invasive prenatal testing (NIPT). PremaithaÕs flagship product, the IONA¨ test is the first non-invasive in vitro diagnostic product for prenatal screening, enabling clinical laboratories to offer CE-marked NIPT in-house for the first time. The IONA¨ test estimates the risk of the fetus having Trisomy 21 (DownÕs syndrome), Trisomy 18 (EdwardsÕ syndrome) and Trisomy 13 (PatauÕs syndrome). The IONA¨ test is a complete diagnostic system that is simple and standardised, enabling PremaithaÕs clinical laboratory customers to perform the test in their laboratory, using existing clinical workflow. The IONA¨ test has a higher detection rate and lower false positive rate giving pregnant women, their families and their doctorsÕ greater confidence in the result thereby reducing the need for unnecessary invasive follow-up tests and the associated anxiety and stress. PremaithaÕs strategy aims to accelerate the broad dissemination of advanced NIPT tests to benefit more laboratories, doctors and pregnant women. Premaitha is listed on the London Stock ExchangeÕs Alternative Investment Market (AIM). Its R&D, manufacturing and commercial operation is located on the Manchester Science Park, UK. For further information please visit www.premaitha.com or email iona@premaitha.com.